HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report

Files in This Item:

The file(s) associated with this item can be obtained from the following URL: https://doi.org/10.1186/s12879-021-06091-x


Title: Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report
Authors: Umemura, Machiko Browse this author
Suda, Goki Browse this author →KAKEN DB
Tsukamoto, Shihori Browse this author
Ebata, Ko Browse this author
Takahash, Shinjiro Browse this author
Sasaki, Takashi Browse this author
Nakajima, Sae Browse this author
Hirata, Koji Browse this author
Ozasa, Mariko Browse this author
Takano, Masatoshi Browse this author
Katagiri, Masaki Browse this author
Sakamoto, Naoya Browse this author
Keywords: Glecaprevir
Hepatitis C virus
Pibrentasvir
Direct-acting antiviral
hepatitis C flare
Issue Date: 27-Apr-2021
Publisher: BioMed Central
Journal Title: BMC infectious diseases
Volume: 21
Issue: 1
Start Page: 389
Publisher DOI: 10.1186/s12879-021-06091-x
Abstract: Background In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. However, appropriate therapeutic strategies for managing hepatitis C flare during R-CHOP have not been established, and this issue is complicated by conflicting results regarding the use of direct-acting antivirals in patients with uncontrolled malignancies. Case presentation We report the first case of effective and safe treatment with on-demand 8-week glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in a patient with diffuse large B-cell lymphoma (DLBCL). The patient completed five additional courses of R-CHOP without hepatic toxicity. A complete response of DLBCL and a sustained virological response were observed at 24 weeks after glecaprevir and pibrentasvir completion. Conclusion On-demand, direct-acting antivirals could be a novel strategy for managing hepatitis C flare during R-CHOP.
Type: article
URI: http://hdl.handle.net/2115/82145
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 

 - Hokkaido University